Enliven Therapeutics (ELVN) | Stock Overview & Key Data
Enliven Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $62.71 on June 8, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN | 1.20B Small-cap | 1.42% | -2.02% | 25.98% | -17.47% | -16.61% | -20.82% | 1,603.48% | -3.78% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Vera Therapeutics VERA | 1.38B Small-cap | 0.00% | 3.65% | 21.95% | -45.48% | -45.50% | -37.27% | 44.01% | 99.74% |
| Immunocore Holdings IMCR | 1.56B Small-cap | 1.34% | -7.73% | 35.67% | 10.09% | 11.60% | -17.97% | -25.06% | -24.98% |
| Agios AGIO | 1.93B Small-cap | 5.56% | 7.78% | 47.90% | 1.06% | 13.94% | -23.26% | 57.82% | -34.32% |
Enliven Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Enliven Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is ELVN's 52-week high and low?
In the last 52 weeks, Enliven Therapeutics reached a high of $30.03 (on October 18, 2024) and a low of $13.30 (on April 10, 2025).
What is the market cap and P/E ratio for ELVN?
Curious about Enliven Therapeutics's size and valuation? Its market capitalization stands at 1.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is N/A.
Does ELVN pay dividends? If so, what's the yield?
As for dividends, Enliven Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Enliven Therapeutics's main competitors or similar companies to consider before investing?
When looking at Enliven Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -6.00% | 56.88% |
| Regeneron REGN | 55.27B | Healthcare | Biotechnology | -51.08% | -11.43% |
| Vera Therapeutics VERA | 1.38B | Healthcare | Biotechnology | -37.27% | 44.01% |
| Immunocore Holdings IMCR | 1.56B | Healthcare | Biotechnology | -17.97% | -25.06% |
| Agios AGIO | 1.93B | Healthcare | Biotechnology | -23.26% | 57.82% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Enliven Therapeutics Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Enliven Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for ELVN?
Looking at Enliven Therapeutics's growth, its revenue over the trailing twelve months (TTM) was N/A. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of ELVN stock is held by insiders and institutions?
Wondering who owns Enliven Therapeutics stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.